This is an open-label, multicenter, Phase 1 clinical trial to evaluate the maximum tolerated dose, safety, pharmacokinetic/pharmacodynamic characteristics and preliminary anti-tumor activity of SB17170 when administered alone(1a) and co-administered with standard of care(1b) to patients with locally advanced or metastatic solid tumors who have failed standard of care.~1 cycle of treatment of this clinical trial is 21 days, and tumors are assessed every 2 cycles.
Phase 1 Open-label, multicenter, dose escalation, dose expansion study